Academician of the Chinese Academy of Sciences: The suspension of production of Kexing

According to the suspension of production of the Kochi crown disease vaccine in China, the academician of the Chinese Academy of Sciences said that the exit of the Kochi vaccine is an inevitable result of iteration of the coronary vaccine.

According to CCTV on Friday (January 12), the academician and immunologist Wei Yuquan of the Chinese Academy of Sciences said that the Corporal Coronation vaccine was developed for primitive and non -mutated coronal viruses.The active vaccine played an important role during the epidemic.

He continued, however, the main popular plants in China at this stage are EG.5 and its sub -branches, and JN.1 mutant strains are also upward.The protection effect of the Koxing vaccine will also weaken.Because of this, relevant national departments are vigorously promoting the listing of XBB crown vaccines.

Wei Yu's full name. In June last year, Chengdu Wesque reorganized the three -valent coronary virus virus trimer protein vaccine in a certain range of emergency use and became the world's first XBB vaccine.In December last year, companies such as Shenzhou cells, Kangxino, Lizhu Group have also launched the announcement of crown vaccines in emergency use."The discontinuation of the Kochi new crown vaccine is the result of the iteration of the new crown vaccine."

Wei Yuquan reminded that the coronary virus has not disappeared and still cannot be taken lightly.According to the law of the spread of virus in the past, China should then usher in a peak of coronary virus infection.The personnel are densely flowing around the Spring Festival, and this wave of peaks is estimated to appear in February and before and after the Spring Festival.

He said that to prevent and reduce the mortality of coronal virus, the most effective and most economical way is still vaccination.Therefore, elderly people 60 and above or those from 18 to 59 years old have more serious basic diseases, people with low immune function, and high -risk people infected with the XBB vaccine to effectively reduce the risk of infection and severe occurrence.

Hong Kong Zhongtong News Agency reported on Wednesday (January 10) that the staff of Kexing Holdings Biotechnology Co., Ltd. confirmed that the Corporal Crown Cruise vaccine has been discontinued, and the company will no longer sell the crown vaccine.